It is during the initial phase of cisplatin-induced emesis that i.c.v. exendin (9-39) reduced emesis by ~40 % indicating involvement of central GLP-1 receptors in the emetic response to this cancer chemotherapeutic agent. This evidence concerns the gene GLP1R and cancer.